<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020743</url>
  </required_header>
  <id_info>
    <org_study_id>VGL101-01.002</org_study_id>
    <nct_id>NCT05020743</nct_id>
  </id_info>
  <brief_title>Natural History Study in Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia</brief_title>
  <acronym>ALSP</acronym>
  <official_title>A Natural History Study of Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vigil Neuroscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vigil Neuroscience, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare,&#xD;
      rapidly progressing, genetic, neurodegenerative disease for which no definitive treatment&#xD;
      options and limited information on the natural history of the disease are available. The&#xD;
      structural, genetic, and neuropathophysiological abnormalities of ALSP lead to the onset of&#xD;
      neurologic symptoms, such as moderate to severe motor and neuropsychiatric impairments. This&#xD;
      natural history study will collect data to contribute to the development of future novel&#xD;
      therapies that focus on the neuropathophysiological features that underlie ALSP and that are&#xD;
      essential to reverse, delay, or stop progression of this debilitating disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Months 6, 12, 18, and 24</time_frame>
    <description>Change from Baseline in structural and volumetric MRI</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>ALSP</condition>
  <arm_group>
    <arm_group_label>Patients with ALSP</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic carriers of the CSF1R gene mutation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Not applicable for a Natural History Study</description>
    <arm_group_label>Asymptomatic carriers of the CSF1R gene mutation</arm_group_label>
    <arm_group_label>Patients with ALSP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ALSP and asymptomatic carriers of CSF1R gene mutations, the causative&#xD;
        mutation for ALSP.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria for both ALSP patients and asymptomatic carriers:&#xD;
&#xD;
        1. Subjects who have documentation of a gene mutation in the CSF1R gene&#xD;
&#xD;
        Key Inclusion Criteria for ALSP patients, only:&#xD;
&#xD;
          1. Subjects who fulfill both of the following criteria (a and b):&#xD;
&#xD;
             a. One or more findings of clinical signs or symptoms in the following categories: i.&#xD;
             Cognitive impairment or psychiatric problem ii. Pyramidal signs on neurological&#xD;
             examination iii. Extrapyramidal signs, such as rigidity, tremor, abnormal gait, or&#xD;
             bradykinesia iv. Epilepsy b. Findings consistent with ALSP on MRI. NOTE: Subjects with&#xD;
             other causes of leukoencephalopathy, including vascular dementia, multiple sclerosis,&#xD;
             or leukodystrophy (e.g., adrenoleukodystrophy, Krabbe disease, metachromatic&#xD;
             leukodystrophy), will be excluded.&#xD;
&#xD;
          2. Subjects who, in the investigator's opinion, have demonstrated clinical progression of&#xD;
             their ALSP within the past year.&#xD;
&#xD;
          3. Subjects who have a cognitive or motor impairment that can affect their ability to&#xD;
             comply with study requirements must have a designated caregiver who spends at least 4&#xD;
             hours per week with them. The caregiver must be able and willing to assist the subject&#xD;
             in complying with the study requirements, be able to provide information during study&#xD;
             visits, and be willing to sign a caregiver ICF.&#xD;
&#xD;
        Key Exclusion Criteria (for all study participants):&#xD;
&#xD;
          1. Subjects with any neurological or psychiatric diseases that can produce cognitive,&#xD;
             motor, or behavioral impairment similar to ALSP, including, but not limited to,&#xD;
             Alzheimer's disease, frontotemporal dementia, ALS, stroke, Huntington disease,&#xD;
             multiple sclerosis, Parkinson's disease, and Down syndrome, or with active&#xD;
             alcohol/drug abuse&#xD;
&#xD;
          2. Subjects who are unable to undergo MRI&#xD;
&#xD;
          3. Subjects with any condition or situation that, in the opinion of the investigator or&#xD;
             sponsor medical personnel, may place the subject at significant risk, confound the&#xD;
             study results, or interfere significantly with the subject's participation in the&#xD;
             study.&#xD;
&#xD;
          4. Subjects who have previously undergone HSCT within 12 months prior to&#xD;
             Screening/Baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Angela Pontius</last_name>
    <phone>+1 857 254 4445</phone>
    <email>trials@vigilneuro.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigative Site 1</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>trials@vigilneuro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigative Site 2</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALSP</keyword>
  <keyword>CSF1R</keyword>
  <keyword>leukoencephalopathy</keyword>
  <keyword>Hereditary Diffuse Leukoencephalopathy with Spheroids</keyword>
  <keyword>HDLS</keyword>
  <keyword>CSF1R-related Leukoencephalopathy</keyword>
  <keyword>Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia</keyword>
  <keyword>CSF1R gene mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukoencephalopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

